1,1'-(1,3-丙烷二基)二胸腺嘧啶 | 22917-75-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 1,1'-(1,3-丙烷二基)二胸腺嘧啶
• 英文名称: 1,1'-trimethylenebis(thymine)
• 英文别名: 1,1'-Trimethylenbisthymin；5-methyl-1-[3-(5-methyl-2,4-dioxopyrimidin-1-yl)propyl]pyrimidine-2,4-dione
• CAS: 22917-75-5
• 化学式: C₁₃H₁₆N₄O₄
• 分子量: 292.294
• InChiKey: BMRBWWWZFYXCDX-UHFFFAOYSA-N

物化性质

• 密度：
  1.294±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  98.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1,1'-(1,3-丙烷二基)二胸腺嘧啶 在 sodium formate 作用下， 以 水 为溶剂， 生成 1,1'-trimethylenebis(5,6-dihydrothymine)
  参考文献：
  名称：

  Conformational Effects on Photophysical Characteristics of C5–C5′-linked Dihydrothymine Dimers in Solution¶

  摘要：

  Photophysical characteristics of N-substituted C5-C5'-linked dihydrothymine dimers (1a,b[meso], meso compounds of [5R,5'S]-bi-5,6-dihydrothymines; 1a,b[rac], racemic compounds of [5R, 5'R]-bi-5,6-dihydrothymines and [5S,5'S]-bi-5,6-dihydrothymines) in aqueous solution with varying contents of less-polar aprotic solvent such as tetrahydrofuran or dioxane have been investigated by UV-absorption, and steady-state and time-resolved fluorescence spectroscopies, Among the CS-CS'-Linked dimers, (5R,5'S)bi-5,6-dihydro-1-methylthymine (la[meso]) showed a redshifted weak UV-absorption band at 270-350 nm and excimer fluorescence emission at lambda (max) = 370 nm with a quantum yield (Phi (F)) of similar to0.1 in phosphate buffer (pH < 10) at 293 Ii, Racemic compound of 5,6-dihydro-1-methylthymine dimer (la[mc]), meso and racemic compounds of 5,6-dihydro-1,3-dimethylthymine dimers (Ib[meso] and Ib[rac]) in phosphate buffer were nonfluorescent under similar conditions. The W-absorption and fluorescence spectral characteristics of 1a[meso] in aqueous solution were interpreted in terms of intramolecular stacking interactions between the dihydropyrimidine chromophores leading to a preferential "closed-shell" conformation both in the ground state and the excited singlet state. In basic solutions at pH > pK(a) = 11.7, the fluorescence quantum yield of la[meso] decreased due to a dominant "open-shell" conformation resulting from the electrostatic repulsion between the deprotonated dihydrothymine chromophores of la[meso] in a dianion form.

  DOI：

  10.1562/0031-8655(2000)072<0719:ceopco>2.0.co;2
• 作为产物：
  描述：

  胸腺嘧啶 在 六甲基二硅氮烷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 1,1'-(1,3-丙烷二基)二胸腺嘧啶
  参考文献：
  名称：

  三重态能量转移与激发态环化反应是光敏联嘧啶二聚化的控制步骤。

  摘要：

  聚亚甲基连接的联嘧啶模型已设计为具有不同的C5取代基和桥长度。用联嘧啶模型选择性辐照2'-甲氧基苯乙酮（2M），即使存在庞大的取代基也能得到环丁烷嘧啶二聚体。C5处的取代影响嘧啶（Pyr）的相对三重态能量（ET（rel））以及分子间能量转移和分子内三重态Pyr *猝灭的空间位阻。光物理研究表明，烷基取代导致ET（rel）值显着降低。证明了Pyr衍生物对2M的三重激发态的猝灭，并建立了它们的猝灭速率常数（kq）。作为一般趋势，含胸腺嘧啶的化合物的kq值高于109 M-1 s-1，而在尿嘧啶和叔丁基尿嘧啶类似物中，kq显着降低。这些数据是在三种不同的情况下进行解释的：（a）三重态能量转移是速率控制步骤，（b）激发态环化是速率控制步骤，并且（c）速率控制步骤随反应而变化。因此，通过在C5处的取代，连接桥的长度或底物浓度上引入变化，可以从由固有二聚化步骤控制的过程切换至能量转移控制的过程。

  DOI：

  10.1021/acs.joc.9b01423

文献信息

• [EN] AGENTS THAT PREVENT OR REPAIR SKIN DAMAGE<br/>[FR] AGENTS PRÉVENANT OU RÉPARANT DES LÉSIONS CUTANÉES
  申请人：UNIV MINNESOTA

  公开号：WO2013106728A1

  公开（公告）日：2013-07-18

  The invention provides compounds of formula I: or a salt thereof as described herein. The invention also provides dermatological compositions comprising a compound of formula I or mixtures of one or more compounds of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for protecting skin or DNA from photodamage or repairing photodamaged skin or DNA.

  该发明提供了如下的I式化合物或其盐，如本文所述。该发明还提供了包括I式化合物或一种或多种I式化合物的混合物的皮肤科学组合物，用于制备I式化合物的方法，用于制备I式化合物的有用中间体，以及用于保护皮肤或DNA免受光损伤或修复光损伤皮肤或DNA的治疗方法。
• [EN] SUNLESS TANNING COMPOUNDS AND COMPOSITIONS<br/>[FR] COMPOSÉS ET COMPOSITIONS DE BRONZAGE SANS SOLEIL
  申请人：UNIV MINNESOTA

  公开号：WO2015003095A1

  公开（公告）日：2015-01-08

  The invention provides sunless tanning compositions comprising a compounds of formula (I): or a salt thereof as described herein as well as methods for tanning mammalian skin by contacting the skin with the compounds of formula (I) or compositions comprising compounds of formula (I).

  该发明提供了一种无日晒的美黑组合物，包括本文所述的化合物(I)的盐，以及通过将皮肤与化合物(I)或含有化合物(I)的组合物接触来晒黑哺乳动物皮肤的方法。
• Triplet Energy Transfer versus Excited State Cyclization as the Controlling Step in Photosensitized Bipyrimidine Dimerization
  作者：Ofelia R. Alzueta、M. Consuelo Cuquerella、Miguel A. Miranda

  DOI：10.1021/acs.joc.9b01423

  日期：2019.11.1

  triplet energy transfer is the rate controlling step, (b) excited state cyclization is the rate controlling step, and (c) the rate controlling step switches along the reaction. Thus, by introducing variations in the substitution at C5, the length of the linking bridge, or the substrate concentration, it is possible to switch from a process governed by the intrinsic dimerization step to an energy transfer-controlled

  聚亚甲基连接的联嘧啶模型已设计为具有不同的C5取代基和桥长度。用联嘧啶模型选择性辐照2'-甲氧基苯乙酮（2M），即使存在庞大的取代基也能得到环丁烷嘧啶二聚体。C5处的取代影响嘧啶（Pyr）的相对三重态能量（ET（rel））以及分子间能量转移和分子内三重态Pyr *猝灭的空间位阻。光物理研究表明，烷基取代导致ET（rel）值显着降低。证明了Pyr衍生物对2M的三重激发态的猝灭，并建立了它们的猝灭速率常数（kq）。作为一般趋势，含胸腺嘧啶的化合物的kq值高于109 M-1 s-1，而在尿嘧啶和叔丁基尿嘧啶类似物中，kq显着降低。这些数据是在三种不同的情况下进行解释的：（a）三重态能量转移是速率控制步骤，（b）激发态环化是速率控制步骤，并且（c）速率控制步骤随反应而变化。因此，通过在C5处的取代，连接桥的长度或底物浓度上引入变化，可以从由固有二聚化步骤控制的过程切换至能量转移控制的过程。
• NMR and UV Study of 1,1′-(<i>α</i>,<i>ω</i>-Alkanediyl)bis[thymine] and 1,1′-(<i>α</i>,<i>ω</i>-Alkanediyl)bis[uracil]
  作者：Toshio Itahara

  DOI：10.1246/bcsj.70.2239

  日期：1997.9

  Treatment of thymine or uracil with Br(CH2)nBr (n = 3—10) in the presence of t-BuOK gave 1,1′-(α,ω-alkanediyl)bis[thymine] or 1,1′-(α,ω-alkanediyl)bis[uracil] together with 1-(ω-bromoalkyl)thymine or 1-(ω-bromoalkyl)uracil. The structures of these products were determined on the basis of the coupling constants between 5- and 3-positions of uracil ring on the 1H NMR spectra. Molecular aggregation of the thymine and uracil rings of these compounds in aqueous solution was studied on the basis of their 1H NMR and UV spectra. A stacking interaction of the two thymine rings linked by shorter polymethylene chains such as trimethylene and tetramenthylene groups was observed.

  将胸腺嘧啶或尿嘧啶与Br(CH2)nBr（n = 3—10）在t-BuOK存在下处理，得到了1,1′-(α,ω-烷烃二基)双[胸腺嘧啶]或1,1′-(α,ω-烷烃二基)双[尿嘧啶]，以及1-(ω-溴烷基)胸腺嘧啶或1-(ω-溴烷基)尿嘧啶。这些产物的结构是基于尿嘧啶环中5位和3位之间的耦合常数在1H NMR光谱上的分析来确定的。基于它们的1H NMR和紫外光谱，研究了这些化合物在水溶液中胸腺嘧啶和尿嘧啶环的分子聚集情况。观察到由较短的聚亚 methylene 链（如三亚甲基和四亚甲基基团）连接的两个胸腺嘧啶环之间存在堆叠相互作用。
• AGENTS THAT PREVENT OR REPAIR SKIN DAMAGE
  申请人：Regents of the University of Minnesota

  公开号：US20140350036A1

  公开（公告）日：2014-11-27

  The invention provides compounds of formula I: or a salt thereof as described herein. The invention also provides dermatological compositions comprising a compound of formula I or mixtures of one or more compounds of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for protecting skin or DNA from photodamage or repairing photodamaged skin or DNA.

  本发明提供了以下式I的化合物：或其盐，如本文所述。本发明还提供了包含式I化合物或一种或多种式I化合物的混合物的皮肤学组合物，制备式I化合物的方法，用于制备式I化合物的中间体以及保护皮肤或DNA免受光损伤或修复光损伤皮肤或DNA的治疗方法。